Partnerships, Licensing, Investments and M&A Deals and Trends for February 2017 in Pharmaceuticals

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$1000
Buy Report View Sample

Published: April 14, 2017 Report Code: GDHC509MD-ST

Select Item

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for February 2017 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, February 2017 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, February 2017 12

2.2.1 Pfizer Raises USD4.2 Billion in Public Offering of Notes 12

2.2.2 Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 12

2.2.3 Seattle Genetics to Enter into Licensing Agreement with Immunomedics 13

2.2.4 Quintiles IMS Prices Public Offering of

3.25% Notes Due 2025 for USD1.5 Billion 14

2.2.5 Bristol-Myers Squibb Raises USD1.5 Billion in Public Offering of Notes 14

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, February 2017 15

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, February 2017 16

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 17

3.1 Pharmaceuticals & Healthcare, Global, M&A, February 2017 17

3.1.1 Top M&A Deals in February 2017 18

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, September 2016– February 2017 19

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, February 2017 20

3.2.1 Top Equity Offering Deals in February 2017 21

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, September 2016– February 2017 22

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, February 2017 23

3.3.1 Top PE/VC Deals in February 2017 24

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, February 2017 25

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, February 2017 26

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, August 2016–February 2017 28

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, August 2016–February 2017 29

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, February 2017 30

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, September 2016– February 2017 31

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), February 2017 32

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, February 2017 33

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2016– February 2017 34

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, September 2016– February 2017 36

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), September 2016– February 2017 37

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2016– February 2017 38

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2017 39

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 2017 39

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 2017 40

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), September 2016– February 2017 41

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), September 2016– February 2017 42

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), September 2016– February 2017 43

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), September 2016– February 2017 45

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, February 2017 46

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, February 2017 46

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, February 2017 47

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 48

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, February 2017 48

5.1.1 Oncology – Deals of the Month 49

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, February 2017 51

5.2.1 Central Nervous System – Deals of the Month 52

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, February 2017 54

5.3.1 Infectious Diseases – Deals of the Month 55

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, February 2017 57

5.4.1 Cardiovascular – Deal of the Month 58

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, February 2017 59

5.5.1 Immunology – Deals of the Month 60

5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, February 2017 62

5.6.1 Gastrointestinal – Deal of the Month 63

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, February 2017 65

5.7.1 Metabolic Disorders – Deal of the Month 66

6 Deal Summary by Geography 68

6.1 Pharmaceuticals & Healthcare, North America Deals, February 2017 68

6.1.1 North America – Deals of the Month 69

6.2 Pharmaceuticals & Healthcare, Europe, Deals, February 2017 71

6.2.1 Europe – Deals of the Month 72

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, February 2017 74

6.3.1 Asia-Pacific – Deals of the Month 75

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, February 2017 77

6.4.1 Rest of the World – Deals of the Month 78

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 79

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, September 2016– February 2017 79

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, September 2016– February 2017 80

8 Further Information 81

8.1 Methodology 81

8.2 About GlobalData 82

8.3 Contact Us 82

8.4 Disclosure information 82

8.5 Disclaimer 83

Frequently asked questions

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2017 in Pharmaceuticals thematic reports
Currency USD
$1,000

Can be used by individual purchaser only

Most Popular
$2,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$3,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2017 in Pharmaceuticals was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
Immuno-oncology in pharma: neoepitope prediction
$250 | December 2023
Pharmaceuticals
New
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Pharmaceuticals
New
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
$250 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Partnerships, Licensing, Investments and M&A Deals and Trends for February 2017 in Pharmaceuticals in real time.

  • Access a live Partnerships, Licensing, Investments and M&A Deals and Trends for February 2017 in Pharmaceuticals dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more